Sotera Health Company

Sotera Health Company (SHC) Market Cap

Sotera Health Company has a market capitalization of .

No quote data available.

CEO: Michael Petras Jr.

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 2020-11-20

Website: https://soterahealth.com

Sotera Health Company (SHC) - Company Information

Market Cap: -|Sector: Healthcare

Company Profile

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.

Analyst Sentiment

82%
Strong Buy

From 10 Active Polls

1Y Forecast: $21.50

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$18

Median

$22

High Bound

$24

Average

$22

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$21.50
▲ +37.64% Upside
Low Target
$18.00
15% Risk
Median Target
$22.00
41% Mid
High Target
$24.00
54% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 SOTERA HEALTH COMPANY (SHC) — Investment Overview

🧩 Business Model Overview

Sotera Health provides outsourced, compliance-driven services to healthcare providers. The offering is anchored in executing regulated workflows that healthcare facilities must maintain under strict environmental, safety, and infection-prevention standards. In practice, the business operates as an extension of hospital operations: it manages defined service scopes (including regulated waste and related safety/compliance functions) and coordinates day-to-day execution through standardized operating procedures, training, documentation, and audit readiness.

A core feature of the model is customer stickiness created by operational integration. Once a facility selects a vendor and embeds the service into its internal processes—staffing plans, escalation paths, reporting cadence, and compliance documentation—replacement typically requires both operational transition work and ongoing regulatory assurance. This shifts the business from “spot purchasing” toward long-cycle service relationships.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated through contract-based services with recurring elements, supplemented by usage-driven or transaction-like components tied to care delivery volumes (e.g., service frequency, waste volumes, and related processing needs). Monetisation generally includes:

  • Recurring service fees under multi-site and multi-year contracts, supported by defined scope execution.
  • Volume and activity-based charges that track operational throughput (driven by facility activity levels and patient volumes).
  • Compliance and implementation work that supports onboarding, audits, and process alignment—often monetised through project-based fees alongside ongoing service.

Margin structure is influenced by labor productivity, scheduling and routing efficiency, contract mix, and the ability to scale standardized processes across customers. Because service quality is regulatory- and safety-linked, operational excellence and training discipline materially affect unit economics and contract renewals.

🧠 Competitive Advantages & Market Positioning

Sotera’s competitive moat is best described as a combination of high switching costs, regulatory barrier depth, and operational integration (an “ecosystem” of compliance execution rather than a single product).

  • High switching costs (process + compliance integration): Replacing a vendor involves retraining, revalidating workflows, and re-establishing documented compliance routines. The customer’s operational risk during transition increases the reluctance to churn vendors.
  • Regulatory and operational barriers: Healthcare compliance execution requires disciplined adherence to safety standards and documentation. Competitors must sustain performance under audit scrutiny to maintain scale.
  • Integrated ecosystem: Customers benefit from a coordinated approach across regulated workflows, reducing fragmentation and administrative burden.

Competitive benchmarking: key competitors include Stericycle (healthcare waste and related services), Daniels Health (healthcare safety, waste solutions, and related regulated services), and Clean Harbors (broader hazardous waste management and services with a healthcare adjacency in certain categories).

Sotera differentiates through its focus on healthcare-specific compliance execution and integrated service delivery, rather than competing as a generalized waste manager. This emphasis matters because the core buying decision in healthcare is tightly coupled to regulatory assurance, operational continuity, and audit-ready documentation—areas where vendors with entrenched healthcare workflows can earn durable service relationships.

🚀 Multi-Year Growth Drivers

The multi-year opportunity is supported by structural demand for compliance and infection prevention practices, alongside ongoing outsourcing of non-core operations by healthcare systems. Key drivers include:

  • Regulatory and compliance tightening: Increasing scrutiny of safety, infection prevention, and documentation increases the value of specialized operators.
  • Outsourcing of operationally intensive functions: Healthcare providers seek to reduce fixed overhead and transfer compliance execution to specialized vendors.
  • Pressure to improve care quality and reduce adverse outcomes: Infection-prevention and safety-aligned workflows tie vendor execution to institutional quality metrics.
  • Multi-site scaling: Expansion opportunities tend to follow existing customer footprints as systems standardize service vendors across facilities.

Over a five- to ten-year horizon, addressable market growth is more likely to come from share gains within compliant outsourced workflows and contract expansion at existing customers than from cyclical end-demand alone.

⚠ Risk Factors to Monitor

  • Labor and operating cost pressure: Service margins can compress if wage inflation outpaces productivity improvements, particularly for labor-intensive workflows.
  • Regulatory and enforcement changes: New or evolving standards may require process re-engineering, retraining, and incremental documentation costs.
  • Contract concentration and renewal dynamics: Customer procurement cycles and performance-based renewals can affect revenue visibility.
  • Quality, safety, and litigation risk: Any operational failure can lead to reputational harm, remediation costs, and potential legal exposure.
  • Competitive intensity: Large waste and healthcare service providers can compete aggressively on price, requiring disciplined contract selection and margin protection.

📊 Valuation & Market View

The market typically values healthcare services like Sotera Health primarily through cash generation and operating margin durability, with common frameworks including EV/EBITDA and, for earlier-stage growth profiles, EV/Revenue. Key valuation drivers include:

  • Evidence of recurring contract economics: contract longevity, renewal rates, and the ability to expand scope.
  • Sustainable margin structure: labor productivity, pricing discipline, and operating leverage.
  • Cash conversion: working capital management and the relationship between service revenue timing and cash receipts.
  • Risk-adjusted execution quality: fewer compliance incidents and strong audit outcomes support premium multiples.

Investors generally apply a discount if service quality risk appears to be rising or if competitive pricing pressure threatens unit economics.

🔍 Investment Takeaway

Sotera Health’s long-term investment case rests on an operational and regulatory moat: high switching costs created by compliance integration, deep barriers from healthcare regulatory execution, and the ability to scale standardized processes across facilities. Growth is expected to be driven more by outsourcing penetration and contract expansion than by cyclical demand, while the principal watch items are labor-cost dynamics, regulatory evolution, and quality execution.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"Headline (2026-03-31, Q1): Revenue $280.0M and Net Income $26.6M (EPS $0.09). YoY vs 2025-03-31: Revenue +10.0% and Net Income turned positive from a $13.3M loss. QoQ vs 2025-12-31: Revenue -7.8% and Net Income -23.7%. Profitability improved YoY but softened sequentially. Gross margin was 52.5% in Q1 2026 vs 53.2% in Q1 2025 (slightly down), while net margin improved to 9.5% from -5.2% YoY. Sequentially, net margin declined (Q4 net margin 11.5% to 9.5%) as interest expense stayed elevated and operating performance cooled: operating income fell from $136.1M (Q4) to $78.9M (Q1). Cash flow quality was mixed: operating cash flow was $29.4M (down from $102.6M in Q4) and free cash flow was -$16.7M in Q1 due to capex. Balance sheet resilience remains solid in liquidity (cash $315.9M; current ratio 2.82), though leverage is high with net debt ~$1.95B and equity down to $622.5M. Shareholder returns look strong on price momentum: the stock is up 55.4% over 1 year with no stated dividends or buybacks in the provided data, indicating total shareholder return is primarily capital appreciation."

Revenue Growth

Neutral

YoY revenue growth was +10.0% ($280.0M vs $254.5M). QoQ revenue declined -7.8% ($280.0M vs $303.4M), indicating some sequential volatility.

Profitability

Positive

Net income improved sharply YoY (to +$26.6M from -$13.3M), with net margin at 9.5% vs -5.2% last year. However, margins contracted QoQ (net margin 11.5% in Q4 to 9.5% in Q1) and operating income fell from $136.1M to $78.9M.

Cash Flow Quality

Caution

Operating cash flow dropped to $29.4M from $102.6M QoQ, and free cash flow was -$16.7M in Q1 due to capex. No dividends were paid in the period.

Leverage & Balance Sheet

Fair

Liquidity is strong (current ratio 2.82; cash $315.9M). Still, leverage remains elevated with long-term debt ~$2.25B and net debt ~$1.95B; equity declined YoY to $622.5M from $414.1M.

Shareholder Returns

Strong

Strong 1-year price momentum: +55.4%. Dividend yield is shown as 0 and buybacks are not indicated, so total shareholder return appears driven primarily by capital appreciation.

Analyst Sentiment & Valuation

Neutral

Consensus target is $22 vs current price $16.3 (implied upside ~35%). High price multiples (e.g., P/E ~38) suggest valuation is not cheap despite recent profit recovery.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

SHC’s Q1 2026 delivered solid operating momentum: revenues rose 10% to $280M (6.5% constant currency) and adjusted EBITDA increased 10.5% to $135M (6.9% constant currency), with EBITDA margin expansion of over 20 bps. Sterigenics overcame localized weather headwinds (-1.7% volumes) via 4.5% pricing, FX tailwinds, and +1.6% volume/mix, while Q2 growth guidance is framed as a clean comp against last year’s strongest quarter. Nordion stands out with 29% revenue growth (+25.8% constant currency) and more than 290 bps margin expansion to 56.4%, driven by harvest schedule timing. Nelson Labs remained a drag with revenue down slightly (-0.7%) and segment income down -11.5%, though management maintains low-to-mid 30s margin trajectory for full-year as prior Expert Advisory Services headwinds lap. 2026 guidance was reaffirmed, with pricing in the 3%–4% range, interest expense $135M–$145M, and capex $175M–$225M. EO regulation uncertainty is treated as compliance-first, with opportunity depending on final rule timing.

AI IconGrowth Catalysts

  • Sterigenics: 4.5% favorable pricing plus 3.6% foreign currency benefit and +1.6% improved volume/mix, with weather headwind of -1.7% to volumes
  • Sterigenics: strategy execution in higher-growth end markets evidenced by +1.6% volume/mix growth in Q1 despite slow start
  • Nordion: +23.7% volume/mix driven by timing of Cobalt-60 harvest schedules; additional +3.2% FX and +2.1% pricing tailwind
  • Nordion: margins expanded by >290 bps to 56.4% due to higher volume/mix, FX, and favorable pricing (partially offset by inflation)

Business Development

  • Customer conversion referenced for late-year Sterigenics onboarding (details: meaningful, not outsized; built into 2026 outlook)
  • Sterigenics EO-related customer conversion opportunity and dialogue with smaller sterilization providers if new regulations change (mentioned as an opportunity set)

AI IconFinancial Highlights

  • Revenues: +10% YoY to $280M; +6.5% constant currency growth
  • Adjusted EBITDA: +10.5% to $135M; +6.9% constant currency growth
  • Adjusted EBITDA margins expanded over 20 bps in Q1 vs prior-year quarter
  • GAAP net income: $27M, or $0.9 diluted EPS; Adjusted EPS $0.18 (+~29% YoY)
  • Interest expense improved by $6M to $35M, driven ~half by term loan repricing + debt paydown completed late 2025, remainder by lower interest rates
  • Segment margin moves: Nordion +290 bps (to 56.4%); Nelson Labs income margins at 28% (segment income -11.5% YoY) with lower volume/mix partially offset by pricing/FX
  • Sterigenics Q1 volume/mix: +1.6% (weather headwind -1.7% to volumes)
  • Nordion pricing in quarter: ~2.1% (management reiterated Nordion on low end of 3% long-range range due to timing/customer mix)

AI IconCapital Funding

  • Operating cash flow: +$29M in Q1, inclusive of a $34M payment for a previously disclosed legal settlement
  • Adjusted free cash flow positive and expected to accelerate through the year
  • Capex: $46M in Q1, supporting Sterigenics greenfield expansions, EO facility upgrades, and Cobalt-60 development projects
  • Liquidity: >$900M available as of Q1 2026
  • Net leverage ratio: 3.2x at quarter end, nearing long-term target range of 2x–3x

AI IconStrategy & Ops

  • Sterigenics realignment around higher-growth end markets: cross-BU strategic selling emphasized; Q1 showed +1.6% volume/mix growth and satisfaction score improvements (2025 results)
  • Capacity/utilization: company targets ~80% utilization; operational efforts to get more out of existing capacity; modality facility timing—X-ray facility to come online later in 2026; another planned late 2027/early 2028
  • EO emissions compliance execution: ~$200M Sterigenics spend over duration on general facility enhancements; management expects vast majority complete in 2026; guidance assumes current requirements to meet final compliance by safe/compliant operation
  • Downtime commentary: second-half downtime days expected lower; first half headwind year over year, second half tailwind

AI IconMarket Outlook

  • 2026 outlook reaffirmed: Revenue $1.23B–$1.25B (5%–6.5% constant currency growth)
  • 2026 Adj. EBITDA $632M–$641M (5.5%–7% constant currency growth)
  • 2026 FX assumptions: estimated ~100 bps foreign currency benefit to revenue and ~100 bps impact to adjusted EBITDA; FX benefit fully realized in first half; second half ~neutral vs prior year
  • 2026 pricing: midpoint of 3%–4% long-term range; Sterigenics high end, Nordion low end, Nelson Labs low end
  • 2026 Sterigenics: mid- to high-single-digit constant currency revenue growth; Q2 YoY similar to Q1
  • 2026 Nordion: low- to mid-single-digit constant currency growth; H1 revenue ~40%–45% of full-year
  • 2026 Nelson Labs: low single-digit constant currency revenue growth; slight return to growth in Q2; margins low- to mid-30s by full year
  • Interest expense 2026: $135M–$145M
  • Effective tax rate (adj net income): 27%–29%
  • Adjusted EPS 2026: $0.93–$1.01
  • Share count (fully diluted weighted avg): 289M–291M
  • Capex 2026: $175M–$225M
  • Guidance: does not assume any M&A activity

AI IconRisks & Headwinds

  • Sterigenics volume headwind from localized U.S. weather in Q1: -1.7% to volumes
  • Sterigenics inflation/inputs noted as controlled; however key inputs remain labor and gas/cobalt (risk of cost volatility)
  • EO emissions regulation uncertainty: potential rule changes could affect timing/opportunity and near-term CapEx framing, though management is executing current-compliance plan
  • Nordion Q1 pricing variability around low-end 3% long-range range due to timing/customer mix (risk of quarter-to-quarter pricing fluctuations)
  • Nelson Labs Q1 headwind: segment income -11.5% YoY; driven by lower volume/mix and margin pressure (28% margins)

Q&A: Analyst Interest

  • Sterigenics volume visibility & weather impact: Management said Q1 started soft in January/February due to weather but March was the best volume month in 3–4 years, with April starting strong. They expect Q2 constant-currency growth similar to Q1, emphasizing comp vs last year’s strong Q2, not structural slowdown.
  • Nelson Labs headwinds (Expert Advisory Services) & margin trajectory: Management explained Nelson Labs met expectations and that Expert Advisory Services was the last quarter of a headwind being lapped. They cited testing volumes slightly down but routine volumes returning; routine testing correlates with sterilization volumes. Margins should rise to low-to-mid 30s full-year, consistent with prior guidance.
  • EO emissions regulations scenarios & CapEx implications: Management addressed the possibility of scaling back ethylene oxide emissions rules, but stated they are proceeding as if the existing rule remains the requirement. They referenced ~$200M spend on EO general facility enhancements over the duration, aiming for vast majority complete in 2026, and said remaining timing/opportunity depends on final rule content and when it takes effect.

Sentiment: MIXED

Note: This summary was synthesized by AI from the SHC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
© 2026 Stock Market Info — Sotera Health Company (SHC) Financial Profile